Background-Drug-eluting stents are more effective in reducing restenosis than bare-metal stents. Less certain is the relative performance of 2 widely used drug-eluting stents-sirolimus-and paclitaxel-eluting stents-in diabetic and nondiabetic patients undergoing percutaneous coronary intervention in routine clinical practice. We therefore studied the long-term effectiveness and safety of sirolimus versus paclitaxel stents overall and stratified by the absence or presence of diabetes. Methods and Results-We compared sirolimus and paclitaxel stents in a propensity-score matched cohort of 2054 pairs of patients (835 matched pairs of diabetic patients and 1219 matched pairs of nondiabetic patients) undergoing percutaneous coronary intervention in Ontario between December 1, 2003 and March 31, 2006. The cohort was derived from the Cardiac Care Network of Ontario percutaneous coronary intervention registry and linked to population-based administrative health databases. In the overall cohort, there was no difference in rates of target-vessel revascularization (Pϭ0.47), myocardial infarction (Pϭ0.71), or death (Pϭ0.49). As compared with paclitaxel stents, the use of sirolimus stents was associated with a significantly lower 3-year rate of target-vessel revascularization in nondiabetic patients (8.3% versus 10.0%, Pϭ0.01), but not in diabetic patients (12.7% versus 10.3%, Pϭ0.07). Rates of all-cause mortality were similar in patients receiving sirolimus stents versus paclitaxel stents in both the diabetic (8.4% versus 9.2%, Pϭ0.91) and nondiabetic (4.6% versus 3.0%, Pϭ0.22) groups. Conclusions-In this large observational study, patients receiving paclitaxel and sirolimus stents had similar mortality rates, but nondiabetic patients receiving sirolimus stents were significantly less likely to require repeat revascularization. (Circ Cardiovasc Qual Outcomes. 2009;2:96-107.)
S irolimus and paclitaxel stents, the first 2 types of drugeluting stents to be widely marketed and used in North America, have been found to be more effective than baremetal stents in reducing the need for repeat revascularization after percutaneous coronary intervention (PCI). [1] [2] [3] Although a number of studies have compared the relative performance of these 2 drug-eluting stent systems, the results have been inconsistent. Some trials have demonstrated similar rates of repeat revascularization associated with the 2 stent types, 4, 5 whereas others have reported lower rates of angiographic and clinical restenosis in patients receiving sirolimus stents. 6 -8 There is also uncertainty about the relative effectiveness and safety of paclitaxel versus sirolimus stents in coronary artery disease patients with diabetes mellitus, a population at a disproportionately higher risk of atherosclerosis and in-stent restenosis than its nondiabetic counterpart. 9 -13 A major lim-itation of earlier studies has been a lack of adequate sample size to demonstrate superiority of one drug-eluting stent over the other among diabetic patients. 14 
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In this study, we present results of a comparison of paclitaxel versus sirolimus stents in a large population-based sample of patients undergoing PCI in Ontario, Canada. Rates of target-vessel revascularization, myocardial infarction, death, and a composite of nonfatal myocardial infarction or death were examined in propensity-score matched samples of patients followed for up to 3 years. A few previous studies have suggested, but not confirmed, that the 2 drug-eluting stent types vary in their effectiveness depending on the presence or absence of diabetes. 15, 16 We therefore studied patient outcomes in both the overall cohort and separately in patients with and without diabetes.
SUMMARY
• Little is known about the relative performance of sirolimus-and paclitaxel-eluting stents in diabetic and nondiabetic patients with coronary artery disease in routine clinical practice. • This study examined the long-term effectiveness and safety of sirolimus versus paclitaxel stents in patients who underwent percutaneous coronary intervention in Ontario between December 1, 2003 and March 31, 2006 . • Rates of target-vessel revascularization, myocardial infarction, and death were compared in the propensity-score matched cohort of 2054 pairs of patients and separately among the 835 matched pairs of diabetic patients and the 1219 matched pairs of nondiabetic patients. • In the overall cohort, there was no significant difference in 3-year rates of target-vessel revascularization (Pϭ0.47), myocardial infarction (Pϭ0.71), or death (Pϭ0.49). • Rates of all-cause mortality were similar in patients receiving sirolimus stents versus paclitaxel stents in both the diabetic (8.4% versus 9.2%, Pϭ0.91) and nondiabetic (4.6% versus 3.0%, Pϭ0.22) groups. • A key finding of this study was the interaction between diabetes status and the effectiveness of sirolimus versus paclitaxel stents, where sirolimus stents were significantly more effective in reducing the need for target-vessel revascularization in nondiabetic patients (8.3% versus 10.0%, Pϭ0.01) but not in diabetic patients (12.7% versus 10.3%, Pϭ0.07). • Greater awareness of these findings may lead to better choice of drug-eluting stents in patients and reduced need for repeat revascularization in the future.
Methods

Study Population
Our study cohort was derived from the prospective clinical registry of the Cardiac Care Network of Ontario, which includes all patients undergoing cardiac procedures in the 12 PCI centers in Ontario. All procedures are funded under the government's universal health insurance plan. Cardiac-procedure referral forms and patient charts are reviewed by Cardiac Care Network nurse coordinators to gather registry information, including patient demographic characteristics, cardiac history, and medical conditions, as well as PCI procedure data, such as lesion location and stent type, length, and diameter. Data from the Cardiac Care Network registry were supplemented by linking to population-based administrative databases, including the Canadian Institute for Health Information's hospital-discharge abstract database 17 for patient's comorbidities, and Statistics Canada's census data 18 for median household income from which patient-level income quintiles were derived. Diabetes status was verified using the Ontario Diabetes Database, a registry that has been validated against primary care health records and has been shown to identify patients with diabetes with high sensitivity (86%) and specificity (97%). 19, 20 For the current study, we identified patients who underwent a PCI between December 1, 2003 and March 31, 2006 with placement of a single sirolimus-eluting stent (Cypher; Cordis, Johnson & Johnson), a single paclitaxel-eluting stent (Taxus, Boston Scientific), or multiple drug-eluting stents of the same type. For each patient, the first PCI within the study period was chosen as the index procedure. Individuals with coexisting conditions (ie, dementia, secondary cancer, and moderate or severe liver disease), missing information on potentially important prognostic factors (eg, age, socioeconomic status, lesion location, or Canadian Cardiovascular Society angina classification), and those who had undergone a PCI in the past year were excluded from the cohort. Because linkages with multiple databases were performed using unique encrypted health card numbers, patients with invalid Ontario health card numbers were also excluded.
The study cohort was linked to clinical and administrative databases to ascertain clinical outcomes. Target-vessel revascularization was defined as a follow-up PCI performed on the same vessel as the index PCI (with or without stent implantation), or coronary-artery bypass grafting. Admissions for myocardial infarction (codes I21 and I22 in the International Classification of Diseases, 10th Revision) were identified from the Canadian Institute for Health Information discharge abstract database, 21 and all-cause mortality was identified from the Ontario Registered Persons Database. Data on all outcomes were available up to and including March 31, 2007, providing at least 1 year of follow-up for every patient in our cohort.
Choice of Drug-Eluting Stent Type
In Ontario, during the study period, each hospital received a fixed amount of funding from the government that allowed it to purchase drug-eluting stents for Ϸ40% of all patients undergoing PCI procedures at their institution. 1 Individual institutions then negotiated contracts with the 2 stent manufacturers. Because paclitaxel stents had a lower price than sirolimus stents in Ontario, most institutions purchased more paclitaxel stents. The choice of drug-eluting stent for each patient, however, was left to the discretion of individual operators at each institution.
Ethics Approval and Role of Funding
Ethics approval for this study was granted by the Research Ethics Board at Sunnybrook Health Sciences Centre. Written consent from patients was not required because participation in the Cardiac Care Network registry is mandated under Ontario's health information privacy legislation. This study was conducted using the funding entirely from public sources. There was no industry involvement in the study design, data collection, data analysis, or writing of the report.
Statistical Analysis
Using univariate analysis, we identified a total of 22 factors (Table  1 ) that were significantly associated with at least 1 of the 3 main study outcomes, ie, target-vessel revascularization, myocardial infarction, or death. We used t tests for means and 2 tests for proportions to compare the prevalence of risk factors in the paclitaxel versus sirolimus stent groups before propensity-score matching.
Propensity-score matching methods [22] [23] [24] used in this study are described in detail elsewhere. 1 Briefly, a propensity score was derived for each patient using the 22 factors listed in Table 1 . A greedy, nearest neighbor 1:1 matching algorithm was used to match subjects on the logit of the propensity score (using calipers of width equal to 0.2 times the standard deviation of the logit of the propensity score) and on diabetes status. Standardized differences were used to compare the measured baseline characteristics between the 2 groups. A standardized difference of Ͻ0.1 was considered indicative of good balance. 25 Event-free survival curves for all clinical end points were constructed by means of the Kaplan-Meier method. The Kaplan-Meier survival curves were compared using a test proposed by Klein and Moeschberger that is similar in form to the McNemar test for comparing correlated binary proportions. 26 We performed a sensitivity analysis using multivariate Cox proportional-hazards regression models on the entire unmatched sample of patients who met study eligibility. Hazard ratios and 95% CIs were adjusted for the 22 clinically relevant characteristics listed in Table 1 , and the potential interaction between diabetes status and the effectiveness of the 2 stent types was tested. In all analyses, the rates of outcome between paclitaxel and sirolimus stents were compared in the overall cohort and then separately for diabetic and nondiabetic patients.
All statistical tests were 2-sided, and probability values of Ͻ0.05 were considered statistically significant. Statistical analyses were performed with the use of SAS software, version 9.1 (SAS Institute, Inc) and the R programming language.
The authors had full access to the data and take responsibility for its integrity. All authors have read and agree to the manuscript as written.
Results
Characteristics of Patients and Procedures
Before Propensity-Score Matching From December 2003 to March 2006, a total of 13 797 patients received either a sirolimus-eluting stent or a paclitaxel-eluting stent in PCI procedures in Ontario. After applying the study's exclusion criteria, 10 089 patients were included in the unmatched cohort. Table 1 shows the characteristics of 2125 patients with sirolimus stents and 7964 patients with paclitaxel stents. Paclitaxel-eluting stents were selectively implanted in patients who were hypertensive, more likely to have had a recent acute myocardial infarction, and more likely to have undergone a previous PCI more than a year before the index stent procedure. The mean stent length was 4.8 mm longer in patients with sirolimus stents than in those with paclitaxel stents; however, mean stent diameter differed by less than one tenth of a millimeter between the 2 groups.
The overall percentage of patients in our unmatched cohort who received the sirolimus stent was 21.1%; however, the percentage ranged from 10.1% to 34.8% during the 28 months of cohort accrual (Appendix Figure 1A) . The mean follow-up period was 67 days longer in the paclitaxel-stent group than in the sirolimus-stent group (PϽ0.001).
After Propensity-Score Matching
Matching on the propensity score and diabetes status resulted in the formation of 2054 matched pairs of patients in the overall cohort. All 22 characteristics, including the mean number of days of follow-up (Appendix Figure 1B) , were well balanced between the paclitaxel-and sirolimus-stent groups (standardized differences Ͻ0.04; Table 2 ). The mean duration of follow-up was 708 days and 707 days in the paclitaxel-and sirolimus-stent groups, respectively. All variables were also well balanced among the 835 matched pairs of diabetic patients (standardized differences Ͻ0.09) and among the 1219 matched pairs of nondiabetic patients (standardized differences Ͻ0.07; Table 2 ).
Rates of Target-Vessel Revascularization
The median duration of follow-up for revascularization was 619 days in the sirolimus-stent group and 618 days in the paclitaxel-stent group. Overall, in the propensity-score matched sample, the rates of target-vessel revascularization were similar in the sirolimus-stent and paclitaxel-stent groups throughout the 3-year follow-up period (Pϭ0.47; Figure 1 , Table 3 ). However, in the diabetic and nondiabetic groups, the 2 drug-eluting stent types differed in their impact on repeat procedures. Among the diabetic patients, the 3-year rate of target-vessel revascularization was higher in the sirolimus-stent group (12.7%) than in the paclitaxel-stent group (10.3%) but did not approach statistical significance at the 5% level (Pϭ0.07). In contrast, among the nondiabetic patients, the rate was significantly lower in the sirolimus-stent group (8.3%) than in the paclitaxel-stent group (10.0%, Pϭ0.01; Figure 1 , Table 3 ).
Rates of Myocardial Infarction and Death
In the overall matched sample, the 3-year rates of myocardial infarction after PCI did not differ significantly between the sirolimus-stent (4.6%) and paclitaxel-stent (5.7%) groups (Pϭ0.71; Table 3 ). As shown in Figure 2 , the 3-year rates of mortality were also similar between the sirolimus-stent (6.1%) and paclitaxel-stent (5.5%) groups (Pϭ0.49), as were the rates observed for the composite outcome of nonfatal myocardial infarction or death (Pϭ0.79). In diabetic patients, paclitaxel stents showed favorable myocardial infarction-free survival in the first 2.6 years, but this trend did not continue throughout the 3-year study period. Among nondiabetic patients, the rates of myocardial infarction were similar in the 2 stent groups throughout the follow-up period (Pϭ0.17). Death rates did not differ significantly in patients with sirolimus versus paclitaxel stents in either the diabetic (8.4% versus 9.2%, Pϭ0.91) or nondiabetic (4.6% versus 3.0%, Pϭ0.22) groups.
Rates of the composite end point, myocardial infarction or death, were also similar between the sirolimus-stent and paclitaxelstent groups in the patients with (Pϭ0.47) and without (Pϭ0.71) diabetes (Figure 2 , Table 3 ). Table 4 displays the results of the multivariate Cox proportional-hazards regression analysis of the unmatched sample of 10 089 patients. The results of this sensitivity analysis were generally consistent with the Kaplan-Meier survival analysis of the propensity-score matched cohort, with some differences in the results for myocardial infarction in diabetic patients. The all-patient cohort showed nonsignificant relationships between drug-eluting stent type and clinical outcomes. A significant interaction (PϽ0.01), however, emerged between diabetes status and risk of target-vessel revascularization associated with the 2 stent systems. When sirolimus and paclitaxel stents were compared in diabetic and nondiabetic groups, sirolimus stents were associated with a hazard ratio (95% CI) of 1.31 (1.01 to 1.69) among diabetic patients and a hazard ratio (95% CI) of 0.72 (0.56 to 0.93) among nondiabetic patients. The hazard ratios for the remaining analyses were nonsignificant (Table 4 ).
Sensitivity Analysis
Discussion
In this population-based study, we compared the long-term effectiveness and safety of sirolimus and paclitaxel stents in a propensity-score matched sample of 2054 pairs of patients (835 pairs of diabetic patients and 1219 pairs of nondiabetic patients). There was no major difference between paclitaxel and sirolimus stents in the overall cohort. An important observation in our study was that the 2 types of drug-eluting stents differed in their impact on clinically important restenosis among patients with and without diabetes. Sirolimus stents were more effective in reducing target-vessel revascularization in nondiabetic patients, but trended toward being 15 Our study findings are also supported by evidence from a previous indirect meta-analysis in which sirolimus stents outperformed paclitaxel stents with respect to preventing restenosis and target-lesion revascularization in nondiabetic patients but showed no superiority over paclitaxel stents in patients with diabetes. 16 Despite differences in the effectiveness of paclitaxel and sirolimus stents in reducing revascularization in patients with or without diabetes, the 2 devices conferred similar risks of major adverse outcomes irrespective of diabetes status. The 2 drug-eluting stent types were comparable in terms of allcause mortality and a composite of myocardial infarction and death throughout the 3-year period after stent implantation. These findings are consistent with data from the Danish Organization on Randomized Trials With Clinical Outcome II (SORT OUT II) randomized trial, which followed patients for Ϸ18 months, 4 as well as a meta-analysis of 16 randomized trials with a median follow-up period of 24.3 months, 7 thus reaffirming that the 2 drug-eluting devices are similar with regard to safety outcomes up to 3 years.
The results from our propensity-score matched analysis were verified by applying multivariate Cox proportional hazards regression analysis on the large unmatched cohort. In particular, when rates of target-vessel revascularization were compared in the 2 drug-eluting stent systems, we found a significant interaction between diabetes and stent type. Sirolimus stents were associated with a significant 31% increased risk in diabetic patients, but a significant 28% decreased risk in nondiabetic patients. The fact that 2 independent statistical methods, namely covariate-adjusted Cox proportional hazards modeling of unmatched samples of diabetic and nondiabetic patients and Kaplan-Meier analysis on propensity-score matched cohorts, produced analogous results provides credence to our study findings.
Of interest are the potential biological and pharmacological explanations for the apparent differences in efficacy of the 2 drug-eluting stent types among diabetic and nondiabetic patients. Sirolimus-and paclitaxel-eluting stents provide local delivery of drugs that inhibit vascular smooth muscle cell proliferation, which in turn reduces neointimal hyperplasia and restenosis. Sirolimus is a cytostatic agent that has the ability to inhibit the mammalian target of rapamycin regula- tory protein kinase and block the cell cycle at the G1-S checkpoint. Mammalian target of rapamycin is regulated by growth factors via the phosphoinositide 3-kinase insulin signal transduction pathway, 27 which is degraded in people with diabetes. 28 Paclitaxel, on the other hand, stabilizes microtubules and arrests the cell cycle at the G1 and G2/M junctions. 29, 30 The mechanism by which paclitaxel prevents restenosis is independent of the phosphoinositide 3-kinase pathway 31 and is not affected by insulin resistance. This would suggest that sirolimus may be less effective in diabetic patients than an agent independent of this pathway. A phosphoinositide 3-kinase-related attenuation of sirolimus' effect would not be expected in the nondiabetic population, in which sirolimus-eluting stents have been shown, in this and other studies, 16 to be superior to paclitaxel stents in preventing repeat revascularization. Sirolimus has also been shown to enhance agonist-induced platelet aggregation and secretion, which might impede the drug's effect in diabetic patients, who typically have more complex and diffuse lesions. 9, 10 The current investigation represents the largest populationbased comparison of long-term outcomes in patients receiv-ing paclitaxel versus sirolimus stents and is among the first studies to examine the real-world effectiveness and safety of the 2 types of drug-eluting stents in diabetic and nondiabetic patients. Previous studies, including registry reports, have not had adequate sample size to test differences in rates of clinical restenosis and adverse outcomes among diabetic patients with coronary artery disease. 14, [32] [33] [34] Although a large, real-world randomized, controlled trial of the 2 stent types in diabetic and nondiabetic patients would be the best method to confirm our study findings, it would be expensive and timeconsuming to conduct, and it would be many years before the results of such a trial might be completed and the results available.
Study Limitations
We recognize that this study suffers from the inherent limitations of any observational study. To account for the imbalances in characteristics of the treatment groups, the propensity-score matching technique was applied; however, there may still be some residual confounding by unmeasured 
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factors. Nevertheless, this study provides important information on a highly representative sample of patients who underwent PCI in routine clinical practice. Another limitation of this study is that we lacked information on in-stent lumen loss and in-stent thrombosis. However, clinically important safety end points such as myocardial infarction and death were analyzed. Finally, we did not formally assess the cost effectiveness of the 2 different stent types and associated outcomes.
Conclusion
In conclusion, in this large observational study of paclitaxel and sirolimus stents in a real-world clinical setting, we found that although the 2 drug-eluting stent types were similarly safe in both diabetic and nondiabetic patient populations, sirolimus stents were more effective in reducing the need for target-vessel revascularization in patients without diabetes. Greater awareness of these findings may lead to better choice of drug-eluting stents in patients and reduced need for repeat revascularization in the future. Increased use of sirolimus stents in nondiabetic patients and increased use of paclitaxel stents in diabetic patients might be a strategy for enhancing the real-world effectiveness of drug-eluting stents. 
CLINICAL PERSPECTIVE
Differences in the effectiveness of sirolimus-eluting versus paclitaxel-eluting stents in patients with or without diabetes have been suggested but not confirmed in previous research, due in large part to the limited sample sizes of earlier studies. This large observational study compares paclitaxel and sirolimus stents in propensity-score matched samples of 2054 matched pairs of patients: 1219 pairs of nondiabetic patients and 835 pairs of diabetic patients, derived from a population-based registry of percutaneous coronary intervention patients in Ontario, Canada. In the overall cohort, the 2 stent types showed no difference in their effectiveness (rates of target-vessel revascularization) or safety (rates of myocardial infarction and rates of death). A key finding of our study was a statistically and clinically significant interaction between diabetes status and the effectiveness of sirolimus versus paclitaxel stents. Sirolimus stents were significantly more effective in reducing the need for target-vessel revascularization in nondiabetic patients, but not in diabetic patients, where paclitaxel-eluting stents trended toward a lower rate of target-vessel revascularization. The modifying effect of diabetes on the effectiveness of drug-eluting stents is supported by biological evidence and has important implications for the use of paclitaxel and sirolimus stents and their analogs. The study results could potentially inform physicians' choice of stents and help to enhance the "real-world" effectiveness of drug-eluting stents in reducing the need for repeat revascularization.
